By Bruce Buckley
With nearly 60 products enrolled in the FDA’s Biosimilar Product Development (BPD) program and more on the way, the agency is anticipating surging growth in the follow-on biologic market over the coming years, said Janet Woodcock, MD, the director of the FDA’s Center for Drug Evaluation and Research, in testimony before the House Committee on Energy and Commerce’s Subcommittee on Health hearing on Thursday.
With nearly 60 products enrolled in the FDA’s Biosimilar Product Development (BPD) program and more on the way, the agency is anticipating surging growth in the follow-on biologic market over the coming years, said Janet Woodcock, MD, the director of the FDA’s Center for Drug Evaluation and Research, in testimony before the House Committee on Energy and Commerce’s Subcommittee on Health hearing on Thursday.
However, a lack of funding to meet the expected